Live Analyst Rating Changes 30268 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Thomas Stephan
STIF

Thomas Stephan

Stifel Nicolaus
Wall Street Analyst
★★★☆☆
#2057
on 13Foresight · ranked by our own returns
59%
Success Rate
+3.0%
Average Return
20 of 34 calls profitable · +35.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Thomas Stephan's ratings turned a profit when each position was held for 1 year — averaging +3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

45 Buy 46 Hold 0 Sell
Thomas's Stock Coverage 13 ratings · 2026-09-05
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GKOS
Glaukos
 Sep 04, 2026 BUY Strong Buy
-4.6% avg upside
21 analysts
$190.00
7.51% Upside
 · ·
BLCO
Bausch + Lomb Corporation
 Aug 25, 2026 HOLD Buy
+10.5% avg upside
19 analysts
$16.00
11.43% Downside
 +5.2% ·
STAA
Staar Surgical
 Aug 17, 2026 HOLD Hold
+42.8% avg upside
16 analysts
$28.00
16.51% Upside
 -4.1% ·
TMDX
TransMedics Group
 Aug 13, 2026 HOLD Strong Buy
+7.4% avg upside
15 analysts
$65.00
25.35% Downside
 -6.7% ·
GMED
Globus Medical
 Aug 11, 2026 HOLD Strong Buy
+18.5% avg upside
24 analysts
$85.00
8.84% Upside
 -8.1% ·
RXST
RxSight
 Aug 10, 2026 HOLD Hold
+42.6% avg upside
13 analysts
$7.00
8.57% Upside
 -0.5% ·
SGHT
Sight Sciences
 Aug 06, 2026 BUY Strong Buy
+11.8% avg upside
13 analysts
$8.00
3.37% Downside
 +17.8% ·
OFIX
Orthofix Medical
 Aug 05, 2026 BUY Buy
+203.8% avg upside
15 analysts
$13.00
40.17% Upside
 -6.9% ·
CLPT
ClearPoint Neuro
 Aug 04, 2026 BUY Strong Buy
+57.5% avg upside
7 analysts
$22.00
58.63% Upside
 +8.4% ·
ATEC
Alphatec Holdings
 Jul 08, 2026 BUY Strong Buy
+79.4% avg upside
23 analysts
$13.00
38.82% Upside
 +2.6% ·
CH:ALC
Alcon
 May 21, 2026 HOLD Strong Buy
+24.3% avg upside
35 analysts
$56.52
1.91% Downside
 +7.5% ·
SGP
SpyGlass Pharma
 May 15, 2026 BUY Strong Buy
+52.3% avg upside
6 analysts
$42.00
47.10% Upside
 +21.8% ·
IRIX
Iridex
 May 15, 2024 HOLD Strong Buy
+554.8% avg upside
3 analysts
$2.00
182.26% Upside
 -62.3% ·
🔒 8 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Thomas Stephan — Frequently Asked Questions
How accurate are Thomas Stephan's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Thomas's ratings were profitable over a one-year hold, with an average return of +3.0% per rating, or +35.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Thomas ranked on 13Foresight?
Thomas Stephan is currently ranked #2057 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Thomas cover?
Thomas most recently has ratings on GKOS, BLCO, STAA, TMDX, GMED, RXST, SGHT, OFIX, CLPT, ATEC, CH:ALC, SGP and 1 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.